Trans people in federal prisons are being told their hormone treatment will end: none for new patients, "discontinuation" for current ones. Courts have blocked the policy, and the Supreme Court refused to lift the block. The record supports them.
Sourcesupremecourt.govdocket/docketfiles/html/public/26a416.htmlTransgender rightsPrison health care
Hormone treatment in federal prisons
What happens when prisons interrupt treatment, and what the court record shows.
Treatment decisions belong to the patient, in prison too. A prison sentence takes away a person's liberty. It does not take away their medical care or give the state a veto over their body.
Here is how the policy works. Recent patients get "rapid discontinuation." Long-term patients get "appropriately paced discontinuation." Even the exceptions "should be reevaluated regularly with respect to cessation."
Sourcesupremecourt.gov20260928095518937_Kingdom_Appendix_FINAL.pdf, p. 16The exception for long-term patients opens only after "severe physiological and psychological withdrawal effects." The policy requires the harm to occur first.
Sourcesupremecourt.gov20260928095518937_Kingdom_Appendix_FINAL.pdf, p. 16That harm is real. When the prison system cut hormones before, the people suing reported panic attacks, suicidal thoughts and depression.
Sourcesupremecourt.gov20260928095518937_Kingdom_Appendix_FINAL.pdf, p. 199The prison system's own expert wrote that some patients "may be allowed to continue treatment indefinitely," under a heading that said to assess them individually. When the Bureau's memo quoted that expert, it cut those words.
Sourcesupremecourt.gov20260928095518937_Kingdom_Appendix_FINAL.pdf, p. 54It calls its plans "individualized," yet it rejected "case-by-case determinations" for long-term patients.
Sourcesupremecourt.gov20260928095518937_Kingdom_Appendix_FINAL.pdf, p. 59For now, courts have stopped it. A renewed court order, effective Sept. 15, 2026, requires the prison system to keep providing care. On Oct. 21, 2026, the Supreme Court denied the government's request to pause that order.
Sourcesupremecourt.govdocket/docketfiles/html/public/26a416.htmlThe court found the government made no showing of harm to itself: "Defendants do not make any showing that they will be irreparably injured absent a stay." The harm in this case falls on patients.
Sourcesupremecourt.gov20260928095518937_Kingdom_Appendix_FINAL.pdf, p. 204The prison system gives four reasons: the evidence is weak, hormones carry long-term risks, trans prisoners attract violence, and care gives prisoners an incentive to harm themselves. The record answers each one, and none justifies taking anyone's medicine away.
The first stated reason is weak evidence. The policy calls the studies "observational rather than randomized" and finds the care "generally not medically necessary." But a randomized trial exists, and neither the policy nor its expert cites it.
Sourcesupremecourt.gov20260928095518937_Kingdom_Appendix_FINAL.pdf, p. 29In that trial (Nolan et al., JAMA Network Open, 2023), 64 adults seeking testosterone were randomly assigned to start right away or wait three months. Depression was measured with the PHQ-9, a standard questionnaire scored 0 to 27.
Sourcedoi.org10.1001/jamanetworkopen.2023.31919Depression scores fell 5.6 points more with immediate testosterone than with waiting (95% CI 4.4 to 6.8). An improvement of 5 points or more: 19 people (61%) who started, against 4 (13%) who waited.
Sourcedoi.org10.1001/jamanetworkopen.2023.31919Among those with suicidal thoughts at the start (PHQ-9 item 9), the thoughts were gone at three months in 11 (52%) who started testosterone, against 1 (5%) who waited.
Sourcedoi.org10.1001/jamanetworkopen.2023.31919The trial is not the only evidence. A 2025 review commissioned for WHO guidelines compared adults who got hormones with adults who wanted them and did not: hormones "may improve outcomes including depression, quality of life, and suicidality."
Sourcepmc.ncbi.nlm.nih.govarticles/PMC12418855The same review: "No studies identified substantive harms."
Sourcepmc.ncbi.nlm.nih.govarticles/PMC12418855The policy's own sources do not back it. It quotes a 2020 Cochrane review for "insufficient evidence to determine the efficacy or safety" of hormones. That review found "no study met the inclusion criteria."
Sourcepmc.ncbi.nlm.nih.govarticles/PMC8078580A review with no studies in it shows nothing either way; it is not evidence that the care fails. And the policy faults the evidence for not being randomized, while that same source calls placebo-controlled trials of this care "unethical."
Sourcepmc.ncbi.nlm.nih.govarticles/PMC8078580Its own expert does not hold other care to that standard. In a July 2026 Florida trial, the expert agreed that "many medical treatments and mental health treatments are provided that are supported solely by low certainty or low quality evidence."
Sourcesupremecourt.gov20261008145953510_2026.10.08 Respondents Supplemental Appendix - Trump v. Kingdom 26A416.pdf, p. 363Asked whether a treatment lacking high-quality evidence still may be used, since that "is not itself a reason to not utilize that treatment," the expert answered: "That is correct." By the expert's own rule, the first reason fails.
Sourcesupremecourt.gov20261008145953510_2026.10.08 Respondents Supplemental Appendix - Trump v. Kingdom 26A416.pdf, p. 364The same expert testified: "it's often said that you need a randomized control trial in order to get high certainty. That's not accurate."
Sourcesupremecourt.gov20261008145953510_2026.10.08 Respondents Supplemental Appendix - Trump v. Kingdom 26A416.pdf, p. 362The policy cites a 2021 review (Baker et al.) as showing "little (if any) reliable evidence." That review's own summary of 20 studies: "Hormone therapy was associated with increased QOL, decreased depression, and decreased anxiety."
Sourcepmc.ncbi.nlm.nih.govarticles/PMC7894249Elsewhere the prison system quoted the same review only where it found it "impossible to draw conclusions about the effects of hormone therapy on death by suicide," and left out the outcomes where hormones were associated with improvement.
Sourcesupremecourt.gov20260928095518937_Kingdom_Appendix_FINAL.pdf, p. 31In 2023 the Bureau read the same review the other way. Its own clinical guidance cited Baker to say that gender-affirming care "can lessen psychiatric symptoms."
Sourcesupremecourt.gov20261008145953510_2026.10.08 Respondents Supplemental Appendix - Trump v. Kingdom 26A416.pdf, p. 52That 2023 guidance listed "gender affirming treatment" beside "chemotherapy" and "pelvic radiation" as "medically necessary treatment." Nothing in the science changed. The policy did.
Sourcesupremecourt.gov20261008145953510_2026.10.08 Respondents Supplemental Appendix - Trump v. Kingdom 26A416.pdf, p. 59The same guidance warned: "Without treatment, this population may experience higher rates of depression, anxiety, self-harm, and suicidality."
Sourcesupremecourt.gov20261008145953510_2026.10.08 Respondents Supplemental Appendix - Trump v. Kingdom 26A416.pdf, p. 56Its expert calls a 2011 Swedish study (Dhejne et al.) "unfavorable." That study compared patients with the general population, not with untreated patients. Its authors wrote: "Things might have been even worse without sex reassignment."
Sourcejournals.plos.orgplosone/articleUnder oath, the same expert agreed that study did not include "a comparison group of people with gender dysphoria who did not receive treatment."
Sourcesupremecourt.gov20261008145953510_2026.10.08 Respondents Supplemental Appendix - Trump v. Kingdom 26A416.pdf, p. 364After years of providing this care, the court found, the prison system cited "zero evidence from its own medical or mental health professionals," and none that the care "was ineffective or harmful to its own inmates."
Sourcesupremecourt.gov20260928095518937_Kingdom_Appendix_FINAL.pdf, p. 191Its own medical director had sworn the opposite: "The primary care providers at the Bureau safely provide this care within the confines of the prison setting." The government filed that statement itself.
Sourcesupremecourt.gov20260928095518937_Kingdom_Appendix_FINAL.pdf, p. 160The court found the government "failed to seriously consider its own experience providing gender-affirming care to inmates for years under its prior policy."
Sourcesupremecourt.gov20260928095518937_Kingdom_Appendix_FINAL.pdf, p. 192The court found it relied on "a doctor it retained specifically for this litigation, who has limited experience treating gender dysphoria, and who promotes a treatment for gender dysphoria that he himself acknowledges is not evidence based."
Sourcesupremecourt.gov20260928095518937_Kingdom_Appendix_FINAL.pdf, p. 193By the court's account of his testimony, he had treated about 6 to 8 adult patients with gender dysphoria among roughly 20,000 patients over his career.
Sourcesupremecourt.gov20260928095518937_Kingdom_Appendix_FINAL.pdf, p. 197The Bureau's medical director also stated that "there is not a vetted, or validated clinical instrument that measures the success or failure of gender dysphoria treatment." It cannot measure the failure it claims.
Sourcesupremecourt.gov20260928095518937_Kingdom_Appendix_FINAL.pdf, p. 155Yet the policy itself lists the "Utrecht Gender Dysphoria Scale" among its tools for assessing patients. A scale trusted to assess patients can also track how they respond to care.
Sourcesupremecourt.gov20260928095518937_Kingdom_Appendix_FINAL.pdf, p. 13What it offers instead: "Psychotherapy should be prioritized." The court found its expert admitted "no evidence" shows psychotherapy works for gender dysphoria.
Sourcesupremecourt.gov20260928095518937_Kingdom_Appendix_FINAL.pdf, p. 198The court found that psychiatric drugs treat co-occurring conditions, "not the condition of gender dysphoria itself," and that "gender affirming care is the only effective treatment for gender dysphoria."
Sourcesupremecourt.gov20260928095518937_Kingdom_Appendix_FINAL.pdf, p. 198Solo Nichols was prescribed about 13 psychiatric medications from age 14 to 36, with years of psychotherapy. On testosterone, Nichols swore, "I have not had a need for any psychiatric medications." The substitutes are what failed.
Sourcesupremecourt.gov20261008145953510_2026.10.08 Respondents Supplemental Appendix - Trump v. Kingdom 26A416.pdf, p. 291"Testosterone has fixed what so many other medications failed to," Nichols swore.
Sourcesupremecourt.gov20261008145953510_2026.10.08 Respondents Supplemental Appendix - Trump v. Kingdom 26A416.pdf, p. 291The second reason is long-term risk. Its only stated figure, "twenty-two times" the breast-cancer risk, calls trans women "males" and cites a paper on testosterone in trans men. The expert it cites calls the estrogen data on cholesterol "reassuring."
Sourcesupremecourt.gov20260928095518937_Kingdom_Appendix_FINAL.pdf, p. 31A relative risk means little without its baseline. Breast cancer is rare in men, so twenty-two times a rare rate can still be a small absolute risk. Presenting the multiple alone as proof of a large risk is a textbook statistical error.
A 2023 meta-analysis (Corso et al.) gives both: trans women's breast cancer incidence was 22.5 times cis men's (95% CI 5.54 to 91.8), and 0.30 times cis women's (95% CI 0.22 to 0.42), 70% lower. No one cites that to deny estrogen to cis women.
Sourcepubmed.ncbi.nlm.nih.gov36789830In absolute terms, an endocrinologist told the court, the biggest study found "15 cases of breast cancer among 2260 transgender women," a risk about a third of cis women's.
Sourcesupremecourt.gov20261008145953510_2026.10.08 Respondents Supplemental Appendix - Trump v. Kingdom 26A416.pdf, p. 206Clots follow the same pattern. Estradiol about doubles the risk in trans women, to roughly 2.3 cases per 1,000 patients a year. The birth control pill raises it 3.8-fold in cis women. No one takes the pill away from them.
Sourcesupremecourt.gov20261008145953510_2026.10.08 Respondents Supplemental Appendix - Trump v. Kingdom 26A416.pdf, p. 204Plaintiffs' evidence, the court wrote, shows this care "is safe and presents risks comparable to the risks associated with other well-accepted medical treatments, including the use of hormones to treat other conditions in cisgender individuals."
Sourcesupremecourt.gov20260928095518937_Kingdom_Appendix_FINAL.pdf, p. 175Weighing both sides, the court found "a clear winner in the battle of the experts": only plaintiffs offered professionals "with meaningful experience treating people with gender dysphoria."
Sourcesupremecourt.gov20260928095518937_Kingdom_Appendix_FINAL.pdf, p. 197The policy bars hormones only when they are given "to address GD." The same drug for another reason is not touched. A rule aimed at one diagnosis, not at the drug, is not about risk.
Sourcesupremecourt.gov20260928095518937_Kingdom_Appendix_FINAL.pdf, p. 15The expert's other risks are no stronger. He counts 163 FDA reports with no patient total. Among trans U.S. veterans, hormone therapy was not tied to more cardiovascular disease: HR 0.99 (0.89-1.09) in trans women, 0.89 (0.80-0.98) in trans men.
Sourcepubmed.ncbi.nlm.nih.gov40601199Medicine answers long-term risk by watching for it, not by stopping care. The Endocrine Society's guideline calls for lab checks every 3 months in the first year, then once or twice a year, while treatment continues.
Sourceacademic.oup.comjcem/article/102/11/3869/4157558The same guideline calls for bone density checks "in those who stop sex hormone therapy after gonadectomy": after that surgery, stopping is itself a risk. The policy reevaluates even these patients "with respect to cessation."
Sourceacademic.oup.comjcem/article/102/11/3869/4157558The national body that accredits prison health care says the opposite of the policy: "Continue hormone medications" on entry to a facility, and "Initiate hormone medications during incarceration" when clinically appropriate.
Sourcencchc.orgposition-statements/transgender-and-gender-diverse-health-care-in-correctional-settingsThe third stated reason is violence. Trans prisoners do face violence and deserve protection from it. The policy says prisons hold predators who "prey upon inmates who appear feminine." Its response is to take away the targets' care.
Sourcesupremecourt.gov20260928095518937_Kingdom_Appendix_FINAL.pdf, p. 29Trans prisoners are attacked far more often. In the latest federal survey (2023-24), 32.2% of trans people in prison reported sexual victimization, against 3.5% of cis men and 5.2% of cis women.
Sourcebjs.ojp.govcsvpri2324st.pdf, p. 7Trans people held with men fare worst. Among male prisoners whose identity differs from their sex, 34.8% reported sexual victimization, 31.1% by other prisoners, against 3.5% and 1.8% for cis men.
Sourcebjs.ojp.govcsvpri2324st.pdf, p. 8The pattern is not new. In 2011-12, 39.9% of trans people in state and federal prisons reported sexual victimization by other prisoners or staff.
Sourcebjs.ojp.govsvpjri1112_st.pdf, p. 2Removing a victim's medication does nothing to stop an attacker. And on the claim that other prisoners "may begin to resent" patients, the court found the prison system "has not cited a single instance" of this care causing safety problems.
Sourcesupremecourt.gov20260928095518937_Kingdom_Appendix_FINAL.pdf, p. 201The court called that failure "conspicuous": its order had been in place "for more than a year, yet the government provides no evidence of gender-affirming care giving rise to" safety problems.
Sourcesupremecourt.gov20260928095518937_Kingdom_Appendix_FINAL.pdf, p. 201The federal appeals court in Washington agreed in September 2026: the Bureau "makes claims about the security impact of providing gender-affirming care without addressing whether such issues have occurred."
Sourcesupremecourt.gov20260928095518937_Kingdom_Appendix_FINAL.pdf, p. 210Wisconsin defended a hormone ban as security. The evidence showed trans prisoners "may be targets for violence even without hormones," and Atherton, its own security expert, called it "an incredible stretch" that a ban could prevent sexual assaults.
Sourcegovinfo.govUSCOURTS-ca7-10-02339-0.pdf, p. 13Atherton worked in Colorado, which gave prisoners hormones, and testified that policy "was reasonable and had been implemented effectively." The appeals court upheld the finding that the state's evidence "failed to establish any security benefits."
Sourcegovinfo.govUSCOURTS-ca7-10-02339-0.pdf, p. 14Limiting prisoners with cancer to "therapy and pain killers" would plainly be unconstitutional, the court said. "Refusing to provide effective treatment for a serious medical condition serves no valid penological purpose and amounts to torture."
Sourcegovinfo.govUSCOURTS-ca7-10-02339-0.pdf, p. 11Prisons protect patients without taking their medicine. Methadone and Suboxone patients can be targeted too, but those concerns "did not result in the denial of medically necessary treatment," a longtime Bureau psychologist testified.
Sourcesupremecourt.gov20261008145953510_2026.10.08 Respondents Supplemental Appendix - Trump v. Kingdom 26A416.pdf, p. 266"Providing this care improved institutional safety," the same psychologist testified, with "fewer acute mental health crises and suicide watches."
Sourcesupremecourt.gov20261008145953510_2026.10.08 Respondents Supplemental Appendix - Trump v. Kingdom 26A416.pdf, p. 264The court gave "substantial weight" to public safety, as federal law requires, and found "no adverse impacts on public safety" from keeping patients on their care.
Sourcesupremecourt.gov20260928095518937_Kingdom_Appendix_FINAL.pdf, p. 171The policy says security justifies it "even assuming there are medical benefits," yet calls it "reasonable to tolerate some of these security ... concerns" for some patients. By its own account, the concerns can be outweighed.
Sourcesupremecourt.gov20260928095518937_Kingdom_Appendix_FINAL.pdf, p. 57The fourth stated reason is self-harm. The policy says hormones "can create improper incentives for inmates to harm themselves." The court found it "provides no support" for that.
Sourcesupremecourt.gov20260928095518937_Kingdom_Appendix_FINAL.pdf, p. 193The expert paragraph it relies on says a ban on "new hormone treatments" is "likely to lead to the lowest level of self-harm," but cites no study and gives no count. The policy then ends current care too. Neither step has evidence behind it.
Sourcesupremecourt.gov20260928095518937_Kingdom_Appendix_FINAL.pdf, p. 125The government calls the Bureau's own years of treating patients, at most, "anecdotal evidence."
Sourcesupremecourt.gov20260928095458720_Kingdom_Application_FINAL.pdf, p. 24On security, the same filing leans on the Bureau's "experience and expertise."
Sourcesupremecourt.gov20260928095458720_Kingdom_Application_FINAL.pdf, p. 21Yet its self-harm claim rests on one expert's word: "In my experience working in correctional facilities." One doctor's experience counts for the ban; years of the Bureau's own care count for nothing.
Sourcesupremecourt.gov20260928095518937_Kingdom_Appendix_FINAL.pdf, p. 56Cathy Thompson, a Bureau psychologist for over 20 years, saw what care did: "a reduction in self-harm, and greater engagement in programs like education and reentry preparation."
Sourcesupremecourt.gov20261008145953510_2026.10.08 Respondents Supplemental Appendix - Trump v. Kingdom 26A416.pdf, p. 263Thompson on the incentive claim: "If the treatment is available, there would be no reason to take such drastic measures to get care." Before the Bureau reliably provided care, Thompson knew of people "who attempted self-castration."
Sourcesupremecourt.gov20261008145953510_2026.10.08 Respondents Supplemental Appendix - Trump v. Kingdom 26A416.pdf, p. 269A policy that prohibits this care "regardless of medical need," Thompson added, "would create that sense of hopelessness and desperation among people with gender dysphoria that could prompt self-harm."
Sourcesupremecourt.gov20261008145953510_2026.10.08 Respondents Supplemental Appendix - Trump v. Kingdom 26A416.pdf, p. 269The harm in the record runs the other way: it comes from ending care, as the people suing experienced. A slow taper, the court found, will "not prevent the predictable serious harms of denying hormone therapy."
Sourcesupremecourt.gov20260928095518937_Kingdom_Appendix_FINAL.pdf, p. 199When the Bureau lowered Jas Kapule's testosterone, mood swings and depression came back. In March 2026 the dose went back up; Dr. Moore agreed, Kapule swore, "that I needed a higher dose in order to effectively treat my gender dysphoria."
Sourcesupremecourt.gov20261008145953510_2026.10.08 Respondents Supplemental Appendix - Trump v. Kingdom 26A416.pdf, p. 301The government's Oct. 9 reply calls that harm "unfounded and speculative," while saying the plans for these plaintiffs "would discontinue their hormone interventions." Harm already seen when care was cut is not speculation.
Sourcesupremecourt.gov20261009140353124_26A416_Kingdom_Reply_FINAL.pdf, p. 20The policy started from its conclusion rather than from the evidence. The court found the government likely "disregarded significant evidence ... to reach the EO's mandated result": the result a presidential executive order demanded.
Sourcesupremecourt.gov20260928095518937_Kingdom_Appendix_FINAL.pdf, p. 195What should be done: withdraw Bureau of Prisons policy 5260.01 and stop fighting the court order. Provide hormone care to every patient who seeks it, new or current, and stop it only when the patient chooses.
Restore care to anyone already tapered off. Protect trans prisoners by stopping the people who attack them, not by taking away their medicine.
End of thread · Back to the first post